Haleon plc research snapshot
HLN AI stock analysis views Haleon as a global consumer-health company whose H1 2026 results showed accelerating second-quarter organic growth of 3.1%, a higher adjusted operating margin of 24.3%, adjusted diluted EPS up 12%, and net debt down to about 2.5x adjusted EBITDA. The counterweights are a weak respiratory season, slow European growth, Middle East softness, currency, and a valuation that already assumes durable execution. The AI view is a watchlist-to-selective-accumulation framework, not a precise price prediction or personal investment recommendation.
Current price
$9.87
Market cap
$43.08 billion
AI score
70 / 100
Rating
Defensive consumer-health quality with improving momentum, execution and valuation discipline still required
Trend status
Broke above $10 in late July, peaked near $10.32, then pulled back to about $9.87 after in-line H1 results, holding near the 200-day average
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Haleon sells everyday self-care products across Oral Health, VMS, Pain Relief, Respiratory, Digestive, and Therapeutic Skin Health categories. | High |
| Moat | Brands such as Sensodyne, parodontax, Advil, Centrum, Panadol, Voltaren, and Theraflu support shelf access and consumer trust, though private labels and category competition limit pricing power. | Medium-high |
| Management | CEO Brian McNamara and CFO Dawn Allen are executing operating-model savings, margin expansion, buybacks, and a leverage target around 2.5x net debt to adjusted EBITDA. | Medium |
| Financial trend | H1 2026 revenue was £5,602m, up 2.2% reported and 2.6% organic; adjusted operating profit rose 8.2%, adjusted operating margin reached 24.3%, adjusted diluted EPS grew 12% to 10.3p, and free cash flow was £769m. | High |
| Valuation | Using a July 31, 2026 London price reference of 363.3p and FY2025 diluted EPS of 18.5p, the audited calculation is about 19.6x trailing earnings; the forward adjusted multiple is roughly 17x on FY2026E consensus of about 21p. | Medium |
| Technical trend | The ADR broke above $10.00, peaked near $10.32 intraday in late July, then gave back gains after in-line H1 results to close at $9.87, near the 200-day average of $9.78. | Medium |
| Risk level | Key risks are consumer and retailer weakness, a weak respiratory season, slow European categories, Middle East market declines, foreign exchange, debt refinancing, freight and input costs, regulation, and operating-model execution. | High |
| AI confidence | Reported financial and company data are well documented; forward returns remain conditional on execution and valuation changes. | High data confidence |
| Investment certainty | The business is understandable and cash generative with improving momentum, but the entry decision still needs a margin of safety and confirmation that volume and categories broaden beyond Oral Health. | Medium |
HLN AI stock forecast
The HLN AI stock forecast is a scenario framework rather than a promised target. A three-year calculation using FY2026E adjusted EPS of about 21p, a July 31, 2026 reference price of 363.3p, and distinct growth and multiple assumptions produces a wide range of outcomes.
About 600p, or roughly $16 per ADR at a similar FX rate
More likely if organic growth holds near the 3% to 5% FY2026 guide with second-quarter momentum, North America and emerging markets keep improving, respiratory recovers in the second half, margin expansion continues, debt stays near 2.5x, and the market assigns a 22x earnings multiple.
About 450p, or roughly $12 per ADR at a similar FX rate
More likely if adjusted EPS compounds about 6% on top of FY2026E consensus, FY2026 guidance is met, free cash flow supports dividends and buybacks, and the market holds an 18x earnings multiple.
About 310p, or roughly $8.50 per ADR at a similar FX rate
More likely if consumer demand or respiratory seasons stay weak, Europe and the Middle East keep dragging, volumes erode, foreign exchange or freight turns adverse, or the valuation compresses toward 14x earnings.
HLN AI technical analysis
HLN AI technical analysis uses the latest independently available ADR price history through July 31, 2026. The stock closed at $9.87 on July 31 after peaking near $10.32 in late July. These levels are a price-action framework, not a live chart feed, and should be refreshed before any trading decision.
| Level | Value | Why it matters |
|---|---|---|
| Current price reference | $9.87 close on July 31, 2026 | StockAnalysis daily history, last checked August 2, 2026. |
| Immediate support | $9.55 to $9.65 | July pullback lows clustered around $9.60 to $9.63 before the late-July run toward $10.30. |
| Lower support | $9.20 to $9.30 | This zone held repeatedly in late May and June. A sustained break would weaken the recovery thesis. |
| Near resistance | $10.10 to $10.35 | The stock made an intraday high of $10.32 on July 28 and closed near $10.28 on July 29 before the post-results pullback. |
| 50-day moving average | $9.43 | StockAnalysis statistics as of the July 31, 2026 close. |
| 200-day moving average | $9.78 | StockAnalysis statistics as of the July 31, 2026 close; the current price is sitting just above this level. |
| Momentum | RSI about 52.7, broadly neutral | StockAnalysis statistics; not overbought or oversold at the July 31 close. |
| Volume | About 10.7M shares average over 20 days | Volume spiked to about 29M shares on July 29 around the H1 results, an elevated day for the range. |
| Volatility marker | $8.77 to $10.32 from late June to late July | The June 22 low to the July 28 high shows the recent range for risk sizing. |
| Invalidation | Sustained close below $9.20 | A break of the repeated late-May and June support zone would invalidate the near-term recovery setup. |
HLN AI trading strategy
The HLN AI trading strategy is a rules-based research framework, not personal advice. It pairs category and cash-flow evidence with an observable price level and a predefined invalidation condition.
Watch for a close back above $10.10 to $10.35 followed by support holding on a retest. Confirm with volume and evidence that second-half organic growth is tracking the 3% to 5% FY2026 guide.
Treat a close back below the 200-day average near $9.78 or a sustained break below $9.20 as a rules-based invalidation signal.
If HLN revisits $9.55 to $9.65 or $9.20 to $9.30, compare the price action with second-half results, respiratory demand, volume trends, free cash flow, and net-debt progress before assuming support will hold.
Do not average down solely because the company has defensive brands. Size risk for a support failure and changing consumer or retailer conditions.
Track organic revenue by region and category, Oral Health growth, volume versus price, adjusted operating margin, free cash flow, net debt to adjusted EBITDA, buybacks, dividend coverage, and currency effects.
Reassess the thesis if volume/mix stays low, guidance is reduced, leverage moves away from the medium-term target, or savings do not translate into cash returns.
Investment research summary
Haleon sells self-care and over-the-counter health products. Consumers and health professionals pay for recognizable brands, product efficacy, availability, and habitual use in everyday health categories.
Its moat rests on trusted brands, global distribution, retailer shelf space, scientific and regulatory capabilities, and marketing scale. It is not absolute: private labels, rival brands, retailer concentration, and slower category demand can narrow it.
The thesis can fail if consumers trade down, cold and flu seasons stay weak, price increases outpace volume, innovation does not scale, foreign exchange absorbs operating gains, or leverage limits capital allocation flexibility.
Brian McNamara leads Haleon, with Dawn Allen as CFO. The key management tests are delivery of operating-model savings, disciplined brand investment, successful buybacks at sensible valuations, and steady progress toward the roughly 2.5x net-debt-to-adjusted-EBITDA target.
Consumer health benefits from ageing populations, health awareness, self-care, and emerging-market access. It also faces regulation, reimbursement or channel changes, generics and private labels, local competition, and uneven consumer confidence.
At the 363.3p July 31 reference price, the audited calculation is about 19.6x FY2025 diluted earnings and 17.1x free cash flow, with a forward adjusted multiple near 17x. A margin of safety depends on growth and productivity actually improving while debt declines, not on assuming defensive brands will always deserve a premium multiple.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| HLN ADR price | $9.87 close on July 31, 2026 | StockAnalysis price history | August 2, 2026 |
| HLN.L London price | 363.3p close on July 31, 2026 | StockAnalysis LSE quote and Yahoo Finance LSE feed | August 2, 2026 |
| Market cap | $43.08 billion | StockAnalysis statistics | August 2, 2026 |
| Share count and market-cap check | 8.982 billion FY2025 basic weighted-average ordinary shares; 363.3p x 8.982bn = about £32.63bn | Haleon 2025 Annual Report and Pineify financial_rigor.py calculation | August 2, 2026 |
| H1 2026 revenue | £5,602m, up 2.2% reported and 2.6% organic; second-quarter organic growth accelerated to 3.1% from 2.2% in Q1 | Haleon H1 2026 results and Nasdaq/RTT coverage | August 2, 2026 |
| H1 2026 adjusted operating profit and margin | £1,364m, up 8.2%, with an adjusted operating margin of 24.3% | Haleon H1 2026 results | August 2, 2026 |
| H1 2026 adjusted diluted EPS | 10.3p, up 12% from 9.2p in H1 2025 | Haleon H1 2026 results | August 2, 2026 |
| H1 2026 free cash flow | £769m, up from £734m in H1 2025 | Haleon H1 2026 results | August 2, 2026 |
| Net debt | About 2.5x adjusted EBITDA at June 30, 2026, down from 2.6x at Dec. 31, 2025 | Haleon H1 2026 results | August 2, 2026 |
| Interim dividend and buyback | Interim dividend of 2.4p, up 9%; £457m of the planned £500m 2026 buyback completed | Haleon H1 2026 results | August 2, 2026 |
| FY2025 revenue | £11.030 billion, reported decline 1.8%, organic growth 3.0% | Haleon 2025 Annual Report and StockAnalysis | August 2, 2026 |
| FY2026 consensus context | About £11.40 billion revenue and 21p adjusted EPS for FY2026E, with a forward PE near 16.7x | StockAnalysis forecast, analyst estimates not company guidance | August 2, 2026 |
| Analyst price target | Average target $11.75 with a Buy consensus, in a $10 to $13.85 range | StockAnalysis forecast, S&P Global consensus | August 2, 2026 |
This HLN AI stock analysis is an informational research tool only and is not investment advice, a recommendation, or a guarantee of future returns. Forecast scenarios use available public data as of August 2, 2026 and can be wrong if earnings, consumer demand, currency, valuation multiples, or market conditions change.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
